GHCM
TARA icon

Glen Harbor Capital Management’s Protara Therapeutics TARA Stock Holding History

Glen Harbor Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-60
Closed -$5K – 1322
2018
Q4 		$5K Buy
+60
New +$4.24K ﹤0.01% 1273

Other funds holding TARA

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Glen Harbor Capital Management's TARA Position: Q1 2019 in Review

Glen Harbor Capital Management sold out of Protara Therapeutics (TARA) in Q1 2019, closing a stake of 60 shares — an estimated $5K sold.

Glen Harbor Capital Management first reported a position in TARA in Q4 2018 and held it in 1 quarter. The position peaked at $5K in Q4 2018. 14 funds tracked by Wall St. Rank hold TARA as of Q1 2019.

  • Glen Harbor Capital Management reported no remaining Protara Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Glen Harbor Capital Management sold 60 Protara Therapeutics shares in Q1 2019, an estimated $5K.
  • Glen Harbor Capital Management first reported a position in Protara Therapeutics in Q4 2018 and held it in 1 quarter.
  • Glen Harbor Capital Management's Protara Therapeutics position peaked at $5K in Q4 2018.
  • 14 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2019.

Based on Glen Harbor Capital Management's 13F filing for Q1 2019, filed 13 May 2019.